Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Fagan

Showing results (81-90 of 279) with videos related to

Pageof 28
Sort By:
JAMA Neurology|March 29, 2016
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer DiseaseRawan Tarawneh, Gina D'Angelo, Dan Crimmins, et al.
Plos One|May 24, 2013
Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variationRichard J Perrin, Jacqueline E Payton, James P Malone, et al.
EMBO Molecular Medicine|January 6, 2010
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's diseaseAnne M Fagan, Mark A Mintun, Aarti R Shah, et al.
Archives of Neurology|September 14, 2011
Cerebrospinal fluid biomarkers, education, brain volume, and future cognitionCatherine M Roe, Anne M Fagan, Elizabeth A Grant, et al.
Frontiers in Neuroscience|May 2, 2022
Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram SyndromeSarah A Eisenstein, Raveena S Boodram, Courtney L Sutphen, et al.
Neurobiology of Disease|February 15, 2022
Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damageKarin L Meeker, Omar H Butt, Brian A Gordon, et al.
Journal of Alzheimer'S Disease : JAD|July 17, 2010
Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levelsJohn S K Kauwe, Carlos Cruchaga, Sarah Bertelsen, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|July 19, 2016
Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker LevelsGanesh M Babulal, Nupur Ghoshal, Denise Head, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 6, 2019
Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's diseaseIsabelle Bos, Stephanie J B Vos, Suzanne E Schindler, et al.
Science Translational Medicine|December 16, 2016
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injuryMarc Suárez-Calvet, Miguel Ángel Araque Caballero, Gernot Kleinberger, et al.
Pageof 28

Showing results (81-90 of 279) with videos related to

Sort By:
Pageof 28
JAMA Neurology|March 29, 2016
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer DiseaseRawan Tarawneh, Gina D'Angelo, Dan Crimmins, et al.
Plos One|May 24, 2013
Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variationRichard J Perrin, Jacqueline E Payton, James P Malone, et al.
EMBO Molecular Medicine|January 6, 2010
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's diseaseAnne M Fagan, Mark A Mintun, Aarti R Shah, et al.
Archives of Neurology|September 14, 2011
Cerebrospinal fluid biomarkers, education, brain volume, and future cognitionCatherine M Roe, Anne M Fagan, Elizabeth A Grant, et al.
Frontiers in Neuroscience|May 2, 2022
Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram SyndromeSarah A Eisenstein, Raveena S Boodram, Courtney L Sutphen, et al.
Neurobiology of Disease|February 15, 2022
Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damageKarin L Meeker, Omar H Butt, Brian A Gordon, et al.
Journal of Alzheimer'S Disease : JAD|July 17, 2010
Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levelsJohn S K Kauwe, Carlos Cruchaga, Sarah Bertelsen, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|July 19, 2016
Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker LevelsGanesh M Babulal, Nupur Ghoshal, Denise Head, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 6, 2019
Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's diseaseIsabelle Bos, Stephanie J B Vos, Suzanne E Schindler, et al.
Science Translational Medicine|December 16, 2016
Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injuryMarc Suárez-Calvet, Miguel Ángel Araque Caballero, Gernot Kleinberger, et al.
Pageof 28